Inhibitor Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $1.7M | $1.8M | $1.4M | $6.2K | $4.9K | $185.3K | $1.2M |
| SG&A Expense | — | $1.7M | $1.9M | $2.0M | $651.8K | $320.5K | $873.7K | $1.5M |
| Operating Income | — | $-3.4M | $-3.7M | $-3.4M | $-657.9K | $-325.4K | $-1.1M | $-2.7M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | $23.2K | $14.8K | — | — |
| Pretax Income | — | — | — | $-3.0M | $12.2M | $-298.6K | — | — |
| Income Tax Expense | — | — | — | — | $55.1K | $0 | $0 | $0 |
| Net Income | — | $-3.3M | $-3.3M | $-3.0M | $12.1M | $-298.6K | $-1.1M | $-2.7M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.02 | $-0.02 | $-0.02 | $0.03 | $0.00 | $0.00 | $-0.01 |
| EPS (Diluted) | — | $-0.02 | $-0.02 | $-0.02 | $0.03 | $0.00 | $0.00 | $-0.01 |
| Shares Outstanding (Basic) | 172.6M | 172.5M | 172.3M | 172.0M | 366.2M | 376.2M | 373.6M | 370.4M |
| Shares Outstanding (Diluted) | 172.6M | 172.5M | 172.3M | 172.0M | 366.2M | 376.2M | 373.6M | 370.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |